Cancer Metabolism: Fueling More than Just Growth by Lee, Namgyu & Kim, Dohoon
University of Massachusetts Medical School 
eScholarship@UMMS 
UMass Metabolic Network Publications UMass Metabolic Network 
2016-12-01 
Cancer Metabolism: Fueling More than Just Growth 
Namgyu Lee 
University of Massachusetts Medical School 
Et al. 
Let us know how access to this document benefits you. 
Follow this and additional works at: https://escholarship.umassmed.edu/metnet_pubs 
 Part of the Biochemistry Commons, Cancer Biology Commons, Cell Biology Commons, Cellular and 
Molecular Physiology Commons, and the Molecular Biology Commons 
Repository Citation 
Lee N, Kim D. (2016). Cancer Metabolism: Fueling More than Just Growth. UMass Metabolic Network 
Publications. https://doi.org/10.14348/molcells.2016.0310. Retrieved from 
https://escholarship.umassmed.edu/metnet_pubs/20 
Creative Commons License 
This work is licensed under a Creative Commons Attribution-Noncommercial-Share Alike 3.0 License. 
This material is brought to you by eScholarship@UMMS. It has been accepted for inclusion in UMass Metabolic 
Network Publications by an authorized administrator of eScholarship@UMMS. For more information, please contact 
Lisa.Palmer@umassmed.edu. 
Mol. Cells 2016; 39(12): 847-854 
http://dx.doi.org/10.14348/molcells.2016.0310 
 
 
 
 
 
 
 
 
 
Cancer Metabolism: Fueling More than Just Growth 
 
Namgyu Lee1, and Dohoon Kim1,* 
 
 
The early landmark discoveries in cancer metabolism re-
search have uncovered metabolic processes that support 
rapid proliferation, such as aerobic glycolysis (Warburg 
effect), glutaminolysis, and increased nucleotide biosyn-
thesis. However, there are limitations to the effectiveness 
of specifically targeting the metabolic processes which 
support rapid proliferation. First, as other normal prolifera-
tive tissues also share similar metabolic features, they 
may also be affected by such treatments. Secondly, target-
ing proliferative metabolism may only target the highly 
proliferating “bulk tumor” cells and not the slower-
growing, clinically relevant cancer stem cell subpopula-
tions which may be required for an effective cure. An 
emerging body of research indicates that altered metabo-
lism plays key roles in supporting proliferation-independent 
functions of cancer such as cell survival within the is-
chemic and acidic tumor microenvironment, immune sys-
tem evasion, and maintenance of the cancer stem cell 
state. As these aspects of cancer cell metabolism are criti-
cal for tumor maintenance yet are less likely to be relevant 
in normal cells, they represent attractive targets for cancer 
therapy. 
 
 
INTRODUCTION 
1 
The class of drugs known as the antifolates was amongst the 
first successful chemotherapeutics beginning with aminopterin 
developed in the 1940s (Farber and Diamond, 1948), and anti-
folates such as methotrexate and pemetrexed are still widely 
used in cancer therapy (McGuire, 2003; Visentin et al., 2012). 
These drugs competitively inhibit dihydrofolate reductase and 
block the synthesis of tetrahydrofolate, a cofactor required in 
purine biosynthesis and other metabolic functions. Antifolates 
can thus target cancer cells based on their highly proliferative 
nature and requirement for nucleic acids. 
Antifolates and other strategies that also exploit the rapid pro-
liferation of cells, for example DNA- damaging agents such as 
the platins, have proven to be effective tools against cancer. 
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Furthermore, numerous metabolic pathways, such as glycolysis 
and one carbon metabolism, have been shown to be altered in 
cancer cells in a manner that supports rapid proliferation, and 
these remain attractive targets for therapy. 
However, highly proliferating normal cells, such as intestinal 
cells or cells during embryonic development, feature similar 
proliferative metabolism, such as pyruvate kinase M2 isoform 
(PKM2) expression or high folate demand (Barker, 2014; Di 
Francesco et al., 2016; Kim et al., 2015b). Such cells are im-
pacted by these chemotherapeutic strategies, and this be-
comes the basis for side effects, dose limiting toxicities, and 
chemotherapy contraindication in pregnancy. An additional 
limitation is that there are subsets of cancer cells that do not 
display high proliferation rates, and these have been postulated 
to be the chemotherapy resistant, tumor-repopulating “cancer 
stem cells” that confound successful therapy (Moore and Lyle, 
2011; Vinogradov and Wei, 2012). 
On the other hand, when considering the cancer cell within 
its context i.e. the intratumoral environment, it is evident that 
there are specific conditions and demands placed on a cancer 
cell that distinguish it from any normal cell, that may provide 
even more attractive avenues for metabolism-based therapy 
(Fig. 1). First, in the solid tumor environment, due to irregular 
vasculature and rapid growth that outpaces vessel formation, 
many regions lack proper blood flow leading to oxygen and 
nutrient deficiency. Secondly, in addition to stromal involvement, 
there is critical immune cell involvement that both acts against 
or in some cases supports tumor progression. Finally, in sec-
ondary sites of tumor formation or following therapeutic inter-
vention, the maintenance of a cancer “stem cell” population 
may play a key role in repopulating the tumor. Recent research 
suggests that in cancer cells, metabolic activities are altered in 
ways that allow them to overcome these challenges. 
 
ADAPTATION TO INTRATUMORAL METABOLIC STRESS 
 
The combination of limited perfusion to and from the tumor, and 
the metabolic activities of the cancer cells themselves, contrib-
utes to a harsh and toxic environment. The growth of a tumor 
can outpace blood vessel formation; also, tumor vasculature is 
irregular and prone to disruption and collapse (Siemann, 2011). 
Thus, tumor cells, particularly those that are located distally 
from functioning vasculature, are subjected to an environment 
with low levels of oxygen, glucose, amino acids, and other nu-
trients. Many of the metabolic alterations found in cancer cells 
appear to aid their survival within such conditions. In particular, 
a central cancer cell metabolism that aids their survival within 
such an environment is a feature referred to as aerobic glycoly-
sis: regardless of oxygen tension, cancer cells have a high rate 
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Fig. 1. Overview of metabolic mechanisms
involved in adaptation to intratumoral metabolic
stress, maintaining stemness and immune
evasion. Metabolic reprogramming of cancer
cells enhances fitness toward intratumoral
metabolic stress and immune surveillance, and
contributes to maintaining stemness. GLUT1/3,
Glucose transporter 1/3; PKM2, M2 isoform of
pyruvate kinase; SHMT2, Serine hydroxyme-
thyltransferase; LDHA, Lactate dehydrogenase
A; NHE1, Na+/H+-exchanger; MCT1/4, Mono-
carboxylate transporters; CA9, Carbonic anhy-
drase 9; IDH*, Gain-of-function mutation in
isocitrate dehydrogenase1/2; FH*, Loss-of-
function mutation in fumarate hydratase; SDH*,
Loss-of-function mutation in succinate dehy-
drogenase; PHD, Prolyl hydroxylases; HIF1,
Hypoxia-inducible factor 1; KDMs, Histone
lysine demethylases; TET, Ten eleven translo-
cation family of 5-methylcytosine (3mC) hydrox-
ylases; IDO1, Indoleamine-2, 3-dioxygenase 1;
TDO2, tryptophan-2, 3-dioxygenase 2; CD73,
Ecto-5'-nucleotidases; CD39, Ectonucleoside
triphosphate diphosphohydrolase 1. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
of glycolysis and lactate production, with low oxygen consump-
tion. This feature was perhaps the earliest defined biochemical 
characteristic of cancer cells (Warburg, 1956), and supports 
rapid proliferation by diverting glycolytic carbons to biosynthetic 
processes such as the pentose phosphate pathway and serine 
biosynthesis (Hsu and Sabatini, 2008; Vander Heiden et al. 2009). 
Key changes in metabolic gene expression appear to under-
lie aerobic glycolysis. In contrast to most normal cells, cancer 
cells predominantly express the M2 isoform of pyruvate kinase 
(PKM2), which limits phosphoenolpyruvate (PEP) to pyruvate 
conversion and thus overall glucose carbon flux into the TCA 
cycle (Christofk et al., 2008). Furthermore, increased expres-
sion of pyruvate dehydrogenase kinase 1 (PDK1), which phos-
phorylates and inhibits pyruvate dehydrogenase, also acts to 
limit glucose carbon flux into TCA cycle (Kim et al., 2006; 
Papandreou et al., 2006). As the TCA cycle is coupled to oxida-
tive phosphorylation, these changes result in decreased oxy-
gen consumption at the tumor and individual cell level, and 
improve cancer cell survival under oxygen limiting conditions 
(Kim et al., 2006; Papandreou et al., 2006). 
An additional consequence of the hypoxic environment is 
electron transport chain failure and increased production of 
reactive oxygen species (ROS) within cancer cells (Kim et al., 
2006; Klimova and Chandel, 2008). Furthermore, outside of the 
cancer cell, cancer-associated fibroblast or cancer-associated 
macrophages or neutrophils contribute establishment of a 
prooxidant environment (Condeelis and Pollard, 2006; Giannoni 
et al., 2011). Therapeutic strategies such as ionizing radiation 
can further contribute to a prooxidant environment. Decreasing 
carbon flux into TCA can decrease ROS production, and in-
crease cancer cell survival in experimental conditions of hypox-
ia and/or chemically induced ROS (Anastasiou et al., 2011; Kim 
et al., 2006). 
The Warburg phenotype appears to be triggered in large part 
by the tumor microenvironment itself. Hypoxia-inducible factor 1 
(HIF1) is stabilized in hypoxic conditions and induces the ex-
pression of a number of metabolic enzymes and transporters 
involved in central carbon metabolism, including PKM2, PDK1, 
glucose transporters 1 and 3 (GLUT1/3), and lactate dehydro-
genase A (LDHA), all of which contribute to the aerobic glycoly-
sis phenotype (Luo et al., 2011; Semenza, 2012). In addition, 
the tetramerization and activity of PKM2 is induced by levels of 
metabolites such as fructose bisphosphate and serine 
(Chaneton et al., 2012; Christofk et al., 2008), and thus a nutri-
ent limited tumor environment, such as those lacking glucose 
and serine, may limit PKM2 activity, reinforcing the bottleneck 
of carbons into the TCA cycle and the Warburg phenotype.  
As a result of their glycolytic metabolism, cancer cells pro-
duce and excrete high levels of lactate; lactate secretion and 
proton efflux from cancer cells, exacerbated by poor perfusion 
and a hypercellular environment, result in an acidic environ-
ment (pH 5.6-6.8) (Chiche et al., 2010), which poses an addi-
tional challenge for cancer cells. It appears that cancer cells are 
adapted towards this challenge; solid tumors highly express 
carbonic anhydrase IX (CA9), another HIF-1 target, which cata-
lyzes the conversion of CO2 and H2O to HCO3-(bicarbonate), 
which can neutralize low pH (Parks et al., 2011). Furthermore, 
cancer cells overexpress proton-exporting transporters such as 
monocarboxylate transporters (MCTs) and Na+/H+-exchanger 
(NHE1), which allow them to form a pH gradient in which their 
intracellular pH is high relative to their environment (Chiche et 
al., 2010; Webb et al., 2011). 
Elevated expression and functional relevance of serine/glycine 
metabolism enzymes have recently been reported in a variety 
of cancers (Jain et al., 2012; Kim et al., 2015a; Possemato et al., 
2011; Yang and Vousden, 2016; Ye et al., 2014; Zhang et al., 
2012), and appear to play key roles in aiding cell survival in the 
tumor environment. Overexpression of mitochondrial serine 
hydroxymethyltransferase (SHMT2) promotes survival in hy-
poxic and ischemic environments (Kim et al., 2015a; Ye et al., 
2014). This effect of SHMT2 occurs by limiting PKM2 activity 
and thus oxygen consumption (Kim et al., 2015a), and through 
increased one carbon metabolism leading to NADPH produc-
tion and redox control (Fan et al., 2014; Ye et al., 2014). 
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IMMUNE EVASION 
 
The immune system plays a critical role in preventing cancer, 
and avoiding immune surveillance is a hallmark of cancer 
(Hanahan and Weinberg, 2011). Cells of both the innate and 
adaptive immune systems are found in tumors, and how the 
tumor either evades or tolerates this immune component is a 
critical determinant of tumor growth and clinical outcome 
(Gajewski et al., 2013; Galon et al., 2006; Vesely et al., 2011). 
While cancer cells have multiple layers of adaptations that allow 
immune evasion and tolerance, such as downregulation of 
tumor antigens and resistance against immune cell cytotoxicity, 
recent studies show that cancer cells have diverse metabolic 
mechanisms of evading the immune system. 
The aforementioned Warburg metabolism of cancer cells, 
aside from promoting survival within the tumor metabolic envi-
ronment, also contributes to immune evasion. First, the high 
expression of glucose transporters and glucose utilization by 
cancer cells can competitively deplete the glucose required by 
activated T cells in the highly proliferative state, which are also 
glucose dependent (Fox et al., 2005; Pearce and Pearce, 
2013). It was recently shown that the glycolytic intermediate 
PEP is necessary to sustain T-Cell receptor-mediated Ca2+-
NFAT signaling and thus acts as a checkpoint for T-cell activity; 
thus local glucose depletion by tumor cells can not only impair 
T cell proliferation, but T cell activity itself (Ho et al., 2015). 
In addition to the effects of local depletion of glucose, the 
high production of lactate from tumor cell metabolism also acts 
to suppress immune surveillance. LDHA-associated lactic acid 
production and acidification suppresses T and NK cell activa-
tion (Brand et al., 2016; Fischer et al., 2007). An abundance of 
lactic acid in the cancer microenvironment inhibits lactic acid 
export in T cells, thus disrupting their metabolism and function 
(Fischer et al., 2007). Lactate also inhibits monocyte migration 
and cytokine release (Goetze et al., 2011), and dendritic cell 
activation (Gottfried et al., 2006). Furthermore, survival of tu-
mor-associated macrophages (TAM) is impaired by lactic acid 
accumulation in the tumor microenvironment (Carmona-
Fontaine et al., 2013). Lactate promotes the polarization of 
TAM to a M2 state, which has a role in wound healing and im-
munosuppression (Colegio et al., 2014). In this case, however, 
polarization of TAM has an effect of promoting, rather than 
suppressing, tumor growth. 
Enhanced tryptophan catabolism is another immune evading 
mechanism employed by tumors. Many types of cancers over-
express tryptophan-2, 3-dioxygenase 2 (TDO2) and indoleam-
ine-2, 3-dioxygenases 1 (IDO1), which convert the tryptophan 
into kynurenine (Munn and Mellor, 2007). The high utilization of 
extracellular tryptophan by cancer cells can limit utilization of 
tryptophan by T cells, resulting in amino acid deprivation-
associated apoptosis of effector T cells (Fallarino et al., 2002). 
Kynurenine and its downstream metabolites, 3-hydroxykynurenine 
and 3-hydroxyanthranilic acid, induce cell cycle arrest and 
apoptosis of T-cells (Fallarino et al., 2003). Kynurenine also 
suppresses antitumor immune responses by acting as a natural 
ligand for aryl hydrocarbon receptor (Pilotte et al., 2012). How-
ever, the mechanisms which underlie the immunosuppressive 
effects of tryptophan catabolism pathway metabolites in im-
mune cells are still largely unknown. 
Another metabolic mechanism by which cancer cells achieve 
immune escape is through inducing the extracellular accumula-
tion of the purine nucleoside adenosine. Adenosine accumu-
lates in the tumor microenvironment, mainly initiating from a 
mechanism in which ATP is released from cells either through 
injury/necrosis or through altered nucleotide metabolism and 
transport (Antonioli et al., 2013; Stagg and Smyth, 2010). ATP 
is sequentially degraded by the cell surface enzymes CD39 
and CD73 to yield adenosine. Several tumors overexpress 
CD39/CD73, leading to overproduction of adenosine. Addition-
ally, some tumors downregulate nucleotide transporters and 
the cell surface adenosine deaminase CD26, both of which 
normally decrease adenosine levels. Interestingly, the extracel-
lular level of adenosine is dramatically increased in hypoxic 
tissues (Takahashi et al., 2010; Vaupel and Mayer, 2016), via 
induction of CD39/CD73 by hypoxia, which may play a role in 
hypoxic tumor tissues. In turn, extracellular adenosine acts on a 
variety of adenosine receptors (A1, A2A, A2B, A3) on B, T, NK 
and NKT cells, dendritic cells, macrophages, neutrophils, and 
mast cells, leading to downstream signal transduction and sup-
pression of immune functions such as NK cell cytotoxicity, den-
dritic cell maturation, and pro-inflammatory cytokine production 
(Bouma et al., 1997; Eppell et al., 1989; Hasko et al., 1996; 
2008; Hausler et al., 2011; Ryzhov et al., 2011). Thus, adeno-
sine is a physiologically important immune signaling metabolite 
that acts on a variety of immune cells, and this mechanism is 
‘highjacked’ by the altered metabolism of cancer cells.  
 
STEMNESS 
 
Cancer stem cell (CSC) is a term that is used to describe can-
cer cells that possess self-renewal and tumor-seeding proper-
ties (Chen et al., 2013). The specific targeting of CSCs is 
thought to be an important objective in cancer therapy because 
of their observed drug-resistant and tumorigenic properties 
(Chen et al., 2013). Examinations of CSC metabolism have 
reported metabolic characteristics such as a glycolytic pheno-
type and dependence on one carbon metabolism, features that 
are undoubtedly important to CSCs, but do not clearly distin-
guish them from cancer cells in general (Jang et al., 2015; 
Sancho et al., 2016). However, recent evidence indicates that 
metabolic parameters can modulate the stemness of cancer 
cells, suggesting new avenues for therapeutic strategies.  
The metabolite 2-hydroxyglutarate (2HG), referred to as an 
‘oncometabolite’ due to its cancer-promoting properties, regu-
lates the stemness of cancer cells. Wild-type isocitrate dehy-
drogenase 1/2 (IDH1/2) catalyzes reversible conversion of 
isocitrate to -ketoglutarate (-KG) as part of the TCA cycle. 
However, gain-of-function IDH1/2 mutations, found in gliomas 
and myeloid malignancies, cause it to catalyze the conversion 
of -KG to D-2HG (Ward et al., 2010). At high levels, D-2HG, 
due to its structural similarity to -KG, competitively binds and 
-KG-dependent dioxygenases such as the ten eleven translo-
cation family of 5-methylcytosine (3mC) hydroxylases (TETs) 
and the Jumonji C domain-containing histone lysine demethyl-
ases (KDMs), promoting hypermethylation (Chowdhury et al., 
2011; Xu et al., 2011), which results in suppression of genes 
involved in cell differentiation (Losman et al., 2013; Lu et al., 
2012). Indeed, targeting mutant IDH1 or IDH2 promotes cellular 
differentiation and can delay tumor growth (Rohle et al., 2013; 
Wang et al., 2013). Recently, L-2HG, an enantiomer of D-2HG, 
was reported to accumulate in hypoxia via LDHA and malate 
dehydrogenase 1 and 2 (MDH1/2) activity (Intlekofer et al., 
2015). Though D-2HG and L-2HG can exert disparate roles in 
prolyl hydroxylases (PDHs), respectively (Koivunen et al., 2012; 
Terunuma et al., 2014), both D-2HG and L-HG act as a 
suppressor of histone demethylases.  
Loss of function mutations in two other TCA cycle enzymes, 
succinate dehydrogenase (SDH) and fumarate hydratase (FH) 
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Table 1. Working mechanisms of metabolites involved in adaptation to intratumoral metabolic stress, maintaining stemness and immune 
evasion 
 Working enzymes in cancer Metabolites Working mechanism References 
Adaptation to 
intratumoral 
metabolic 
stress 
Pyruvate kinase isozymes M2, PKM2 Decrease in down-
stream glycolytic 
products 
Decreased carbon flux into TCA cycle Christofk et al., 2008
Serine hydroxymethyltransferase, 
SHMT2 
(Serine→Glycine) 
Excessive Glycine 
and NADPH 
Limiting PKM2 activity and thus oxygen 
consumption decrease 
Redox control via production of NADPH 
Fan et al., 2014; Kim 
et al., 2015a; Ye et 
al., 2014 
Carbonic anhydrase 9, CA9 
(CO2, H2O→Bicarbonate, H+) 
Excessive Bicar-
bonate 
Binding with hydrogen forming H2CO3 Parks et al., 2011 
Immune 
evasion 
Lactate dehydrogenase A, LDHA 
(Glucose→Lactate) 
Limited glucose  Limit utility of glucose by T cells→ 
limiting for immune response 
Fox et al., 2005 
Excessive lactate Disturbing T cell metabolism and 
function by inhibition of lactic acid 
export of T cells 
Fischer et al., 2007
Suppression of T and NK cell activation  Brand et al., 2016; 
Fischer et al., 2007
Inhibition of monocyte migration and 
cytokine release 
Goetze et al., 2011 
Inhibition of dendritic cell activation Gottfried et al., 2006
Inhibition of TAM survival Carmona-Fontaine et 
al., 2013 
Polarization of TAM to a M2 state, 
(M2 state TAM has a role in 
immunosuppression) 
Colegio et al., 2014
Indoleamine2,3-
Dioxygenase1/Tryptophan 2,3-
dioxygenase2, IDO1/TDO2 
(Tryptophan→Kynurenine) 
Limited tryptophan Limit utility of tryptophan by T cells → 
amino acid deprivation-associated apop-
tosis of effector T cells 
Fallarino et al., 2002
Excessive 
kynurenine 
Cell cycle arrest and apoptosis of T-cell 
by kynurenine 
Fallarino et al., 2003
Kynurenine acting as a ligand for aryl 
hydrocarbon receptor 
Pilotte et al., 2012 
Ecto-5'-nucleotidases/ Ectonucleoside 
triphosphate diphosphohydrolase1, 
CD39/CD73 
(Nucleotide→Adenosine) 
Excessive adeno-
sine 
Inhibition of T cell response and NK cell 
cytotoxicity 
Hasko et al., 2008; 
Hausler et al., 2011
Suppression of dendritic cell maturation 
and its pro-inflammatory cytokines pro-
duction  
Ryzhov et al., 2011
Activation of immunosuppressive func-
tions of MDSCs 
Ryzhov et al., 2011
Inhibition of phagocytic activity and nitric 
oxide and superoxide production in mac-
rophage 
Eppell et al., 1989; 
Hasko et al., 1996 
Inhibition of neutrophil degranulation  Bouma et al., 1997 
Maintaining 
Stemness 
gain-of-function mutation in isocitrate 
dehydrogenase1/2, IDH1/2 
(KG→D-2HG) 
Excessive 
D-2HG 
Suppression of gene involved in cell dif-
ferentiation 
Losman et al., 2013; 
Lu et al., 2012 
Lactate dehydrogenase A, Malate 
dehydrogenase, LDHA 
MDH1/2 
(KG→L-2HG) 
Excessive 
L-2HG 
(continued) 
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Maintaining 
Stemness 
Loss-of-function mutation in suc-
cinate dehydrogenase, SDH 
(Succinate→Fumarate) 
Excessive 
succinate 
Silencing of crucial genes implicated in cell 
differentiation and EMT 
Letouze et al., 2013 
Activation of a HIF response by the allosteric 
suppression of PHDs 
Isaacs et al., 2005; Selak 
et al., 2005 
Loss-of- function mutation in 
fumarate hydratase, FH 
(Fumarate→Malate) 
Excessive 
fumarate 
Suppression of EMT-related genes Sciacovelli et al., 2016 
Activation of a HIF response by the allosteric 
suppression of PHDs 
Isaacs et al., 2005; Selak 
et al., 2005 
Dihydropyrimidine dehydrogen-
ase 
(5FU→FU-H2) 
Excessive 
dihydropyrimidine
EMT activation Shaul et al., 2014 
Unknown 
Excessive 
dendrogenin A 
Activation of cancer cell differentiation de Medina et al., 2013 
 
 
 
promotes accumulation of succinate and fumarate, respectively 
(Yang et al., 2013). Succinate and fumarate are also known as 
oncometabolites, and similarly to D-2HG promote epigenetic 
alterations by inhibiting the aforementioned group of -KG-
dependent enzymes resulting in global histone and DNA hy-
permethylation (Xiao et al., 2012). In paraganglioma, a neuro-
endocrine tumor, SDH mutation is frequently observed in ma-
lignant tumors (Gimenez-Roqueplo et al., 2003; Neumann et al., 
2004). SDH mutation-related tumors display hypermethylation 
and epigenetic silencing of crucial genes implicated in cell dif-
ferentiation and epithelial-mesenchymal transition (EMT) 
(Letouze et al., 2013). EMT is a developmental process in 
which epithelial cells lose their epithelial characteristics to be-
come motile mesenchymal stem cells, and cancer cells with 
epithelial properties can also undergo EMT to become cells 
with mesenchymal characteristics (Kalluri and Weinberg, 2009). 
This is a significant event as in addition to developing motile 
and invasive properties, cancer cells which undergo EMT are 
thought to obtain stem-cell like properties. In FH-deficient 
mouse and human cells, accumulation of fumarate induces 
EMT by suppression of TET-mediated demethylation of the 
antimetastatic miRNA cluster, which result in expression of 
EMT-related genes (Sciacovelli et al., 2016). 
The impairment of -KG-dependent dioxygenases by 2-HG, 
succinate, and fumarate may also have an additional route in 
which stemness is enhanced: the stabilization of HIF. The acti-
vation of a HIF response is observed in SDH- or FD-deficient 
cancer cells, which could be explained by the allosteric sup-
pression of PHDs by accumulated succinate or fumarate 
(Isaacs et al., 2005; Selak et al., 2005). The activated HIF is 
known to induce the expression of stemness and EMT-related 
genes such as Oct-3/4, Nanog, Sox-2, snail, twist and LOX 
(Mimeault and Batra, 2013). Thus, 2-HG, succinate and 
fumarate might actively regulate stemness of cancer cells by 
activating the HIF response. 
Additional metabolic pathways are emerging as regulators 
cancer cell differentiation. Dihydropyrimidine accumulation by 
dihydropyrimidine dehydrogenase, which catalyzes the rate-
limiting step in pyrimidine degradation, is required in EMT, and 
it was noted that a number of other metabolic enzymes show 
similar mesenchymal-cell-enriched expression patterns that 
indicate they may also be involved in EMT (Shaul et al., 2014; 
2016). Dendrogenin A (DDA), an enzymatic product of the 
conjugation of 5,6a-epoxy-cholesterol and histamine, promotes 
cancer differentiation, which results in suppression of tumor 
growth (de Medina et al., 2013). The underlying mechanisms 
for these functions are not yet well understood. 
CONCLUSION 
 
As overviewed in Fig. 1, the cancer cell faces a set of road-
blocks including a harsh metabolic environment, surveillance 
and attack from the immune system, and the requirement for 
self-renewal - it is not surprising that their metabolic activities 
are altered in ways that enhance fitness toward these challeng-
es. These adaptations, in contrast to cell proliferation, can be 
considered highly specific to cancer cells, and thus hold prom-
ise for future therapeutic strategies. The metabolic enzymes 
described here that support these adaptations (Table 1) are 
catalysts and thus are inherently druggable, interesting targets 
for therapy. As an example, recent clinical trials and FDA ap-
proval of drugs which trigger immune responses against can-
cers (Farkona et al., 2016) have shown great promise, and a 
strategy for blocking the metabolic mechanisms that cancer 
cells use for immune evasion in combination with these drugs 
may be particularly effective. Along these lines, further efforts 
are required to more fully understand how the various metabol-
ic features of cancer cells confound their detection and elimina-
tion by the immune system. As another strategy, based on the 
unique set of challenges that cancer cells face, combinations of 
drugs to hinder multiple aspects of the metabolic adaptations 
described here may be a means to achieve additional selectivi-
ty towards cancer cells. 
While we have outlined some of the recent key discoveries 
into how metabolic activities support cancer activities beyond 
proliferation per se, our understanding of the many ways in 
which altered metabolic activities can benefit a cancer cell is 
likely far from complete. As metabolic activities are tightly inter-
twined with biological processes, unidentified metabolic activi-
ties in cancer cells are likely to support and even drive cancer 
functions not covered here, such as cell migration and evasion 
of apoptosis. Furthermore, there is a complex interplay be-
tween tumor environment, the immune component, and cancer 
cell “stemness” described here that requires further investiga-
tion and understanding. For example, immune cells themselves 
contribute significantly to the metabolic tumor environment; the 
metabolic environment exerts selective pressure towards cells 
with stem-like properties; and so forth. These complex interac-
tions, as well as the metabolic heterogeneity of the tumor, will 
all have to be taken into consideration when considering thera-
peutic strategies. However, targeting cancer metabolism has 
shown great promise in recent years and it is hoped that efforts 
like those described here to understand the multitude of ways 
they can aid cancer cell fitness will continue to take us in the 
right direction. 
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